Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Breezula is a potential hair loss treatment, but recent updates suggest it may not be as promising as initially thought. Some users express skepticism about its effectiveness based on past results.

KX-826 is considered effective for hair maintenance, with better safety research than RU58841, but lacks positive anecdotes. RU58841 is seen as potentially stronger, but concerns exist about systemic effects; combining anti-androgens with 5AR inhibitors is suggested for better results.

The user is considering switching to topical finasteride or pyrilutamide to stabilize hair loss before a hair transplant, currently using oral minoxidil and finasteride. Suggestions include sticking to the current regimen as it is already potent, and caution against using pyrilutamide from unreliable sources.

Isotretinoin and tretinoin are different; isotretinoin can cause hair loss and has more side effects. Tretinoin may affect minoxidil absorption, and users suggest waiting before applying minoxidil.

GT-20029 is discussed as a potential hair loss treatment, with concerns about its safety and systemic absorption compared to finasteride. Users express skepticism about its effectiveness and safety, noting that it may not surpass existing treatments like finasteride and minoxidil.

L. reuteri, a probiotic, is being explored for its potential benefits in treating androgenic alopecia, possibly enhancing finasteride's effects and reducing inflammation. The user combines this with finasteride, oral minoxidil, and other supplements, noting some improvement in hair loss.

The conversation is about hair regrowth progress using hormone replacement therapy (HRT) with Estradiol and Cyproterone, without using Minoxidil. The user shares progress pictures over 0, 3, and 6 months.

A new hair loss treatment, KX-826, is being discussed as a stronger and safer alternative to RU58841 and finasteride. Opinions are mixed, with some users skeptical about its effectiveness and others considering it as part of their regimen.

The post and conversation are about the high cost and skepticism surrounding pyrilutamide as a hair loss treatment, with comparisons to minoxidil, finasteride, and RU58841. The original poster defends pyrilutamide's effectiveness and criticizes others for dismissing it without proper understanding.

The conversation discusses the potential of Verteporfin for hair regeneration and improving hair transplant surgery to leave no scars. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

The user has been using Minoxidil for 4 years and recently added a derma pen and Trinov to their regimen, but results are inconclusive after 3 months. Some users suggest Trinov is ineffective and recommend alternatives like Clascoterone (Breezula) for better results.

The user experienced hair shedding after increasing minoxidil from 5% to 7% with latanoprost, possibly causing telogen effluvium. They are on HRT with Lupron, Estradiol, and Raloxifene, and are concerned about the shedding's duration.

The conversation discusses the less impressive results of Pyrilutamide (kx-836) in phase 3 compared to phase 2, with a suggestion that a longer study might show more significant results. One user reports personal success with Pyrilutamide, experiencing no further hair loss and gradual regrowth.

RU58841 is a strong non-steroidal antiandrogen for hair loss but may cause cardiovascular issues in some users. Alternatives like Pyrilutamide and Breezula are suggested due to better safety profiles and lower systemic risks.

The post is about Bryan Johnson's hair loss regimen, which includes dutasteride mesotherapy, minoxidil, microneedling, and red laser therapy. The conversation includes discussions about the effectiveness of topical dutasteride and speculation about whether Bryan Johnson has had a hair transplant.

Exploring a potential hair loss treatment using the enzyme AKR1C2 to locally reduce DHT levels. Challenges include enzyme delivery through the skin and high production costs, with gene therapy or stem cells suggested as future alternatives.

The conversation discusses an experiment involving hair loss treatments, including the use of Verteporfin, KY19382, dutasteride, oral and topical minoxidil, AHK-Cu, and microneedling. The experiment aims to test the effectiveness of these treatments in promoting hair growth and healing without scarring, with updates planned every few months.

Beta-sitosterol may inhibit 5-alpha reductase type 2 enzyme, potentially reducing DHT levels and promoting hair growth, similar to finasteride but possibly with fewer side effects. Its effectiveness and side effects compared to other treatments like saw palmetto and finasteride remain uncertain due to limited research.

The conversation is about the legitimacy and affordability of ordering a Minoxidil response test from TrichoGene, an India-based company, as an alternative to Daniel Alain. The user is seeking feedback on whether TrichoGene is a reliable option.

GT20029 is a new hair loss treatment in Phase 3 trials in China, using PROTAC technology to target androgen receptors, potentially with fewer side effects than finasteride and minoxidil. VDPHL01, a second-generation minoxidil, is also mentioned as potentially more effective.

People are interested in trying clascosterone (Breezula) for hair loss, especially those who are too young for finasteride. Some users express concerns about the cost and prescription requirements, while others discuss alternatives like RU58841.

Pyrilutamide and RU58841 are androgen receptor antagonists that block receptors without significantly reducing testosterone or DHT levels. Any indirect effect on androgen levels is likely negligible.

The conversation discusses patient updates on hair loss treatment with Verteporfin after five months, as reported by Dr. Blake Bloxham. Patients voluntarily sent their progress pictures to Dr. Bloxham.

RU58841 not working for hair loss after 10 months. Concerns about purity of experimental drugs.

PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.

Hair cloning and new treatments like ET-02, Veradermics (vdphl01), and wound-induced hair neogenesis show promise but are not yet widely available. Current effective treatments include minoxidil, finasteride, and dutasteride, with early intervention being crucial for better outcomes.

A 37-year-old transgender woman is considering a hair transplant to improve her hairline, as she has minimal hair loss and is on Spironolactone and Estradiol. Users suggest she is a good candidate for the procedure, advising her to research reputable doctors and clinics.

Mixing RU58841 with minoxidil compounded with tretinoin is discussed, with concerns about systemic absorption. Topical dutasteride and finasteride are also mentioned as treatments, with varying personal experiences and concerns about side effects.

The user is experiencing hair loss despite using finasteride three times a week due to side effects and is considering alternatives like topical finasteride, estrogen blockers, or dutasteride. They are also interested in potential treatments like GT20029 and pyrilutamide.

The user underwent a hair transplant in Boston, initially dissatisfied with the results, but later achieved significant improvement in hair density and natural appearance after consulting a different surgeon. They used finasteride, minoxidil, and low-level laser therapy as part of their treatment.